Trial Profile
Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme: a randomised, double blind, multicentre phase II trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2022
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms STOMP
- 01 Sep 2022 Primary endpoint (Progression-free survival rate At 4 months after randomisation) has not been met as per results published in the Lung Cancer
- 01 Sep 2022 Results published in the Lung Cancer
- 08 Nov 2017 Status changed from active, no longer recruiting to completed.